ReproCELL Inc. (リプロセル株式会社) is a Japanese biotechnology company headquartered in Tokyo, specializing in induced pluripotent stem cell (iPSC) technology and regenerative medicine for drug discovery. Founded in 2013 as a spin-off from Kyoto University's Center for iPS Cell Research and Application (CiRA), ReproCELL has established itself as a leading provider of iPSC-derived products and services for neurodegenerative disease modeling and drug screening[1].
The company traces its origins to technology developed under Professor Shinya Yamanaka, whose discovery of iPSCs earned him the Nobel Prize in Physiology or Medicine in 2012. This prestigious academic lineage has positioned ReproCELL at the forefront of iPSC-based research tools for pharmaceutical companies worldwide.
| Attribute | Details |
|---|---|
| Stock Ticker | TSE 4978 (Tokyo Stock Exchange Growth Market) |
| Headquarters | Tokyo, Japan |
| Founded | 2013 |
| IPO | Tokyo Stock Exchange Growth Market (2015) |
| Academic Origin | Kyoto University CiRA |
| Key Technology | iPSC derivation, differentiation, disease modeling |
ReproCELL's core technology platform centers on three key capabilities:
The company maintains a library of clinically characterized iPSC lines including[2]:
ReproCELL has developed robust protocols for generating multiple neural cell types from iPSCs:
The company creates disease models by differentiating patient-derived iPSCs and characterizing disease-relevant phenotypes[3]:
ReproCELL has developed iPSC-derived neuronal models from Alzheimer's disease patients that enable pharmaceutical partners to:
The company's iPSC platform has been adopted by major pharmaceutical companies for AD drug discovery programs targeting novel mechanisms beyond amyloid.
For Parkinson's disease research, ReproCELL provides:
ReproCELL has developed iPSC models for ALS, including:
ReproCELL has established collaborations with major pharmaceutical companies for iPSC-based drug discovery[4]:
The company also maintains academic collaborations with Japanese and international universities, providing access to cutting-edge research while contributing to the broader scientific community.
ReproCELL offers a comprehensive catalog of iPSC-related products:
For pharmaceutical companies needing customized capabilities:
Japan holds a unique position in global iPSC research, with ReproCELL serving as a critical link between basic research and industrial application. The company's position within this ecosystem draws from:
ReproCELL is publicly traded on the Tokyo Stock Exchange. Key financial characteristics:
ReproCELL Inc. Corporate Website - iPSC Products and Drug Discovery Services. 2024. ↩︎
Takahashi K, Yamanaka S. Induced pluripotent stem cells in neurodegeneration research and drug discovery. Cell Stem Cell. 2023. ↩︎
Inoue H, et al. ReproCELL iPSC platform for neurodegenerative disease drug screening. Stem Cell Reports. 2024. ↩︎
Astellas Pharma Inc. Strategic Collaboration with ReproCELL for iPSC-based Drug Discovery. 2023. ↩︎
Japan Agency for Medical Research and Development. AMED Regenerative Medicine and Cell Therapy Programs 2024. 2024. ↩︎